

# Resource Summary Report

Generated by ASWG on Aug 9, 2026

## Ras (G12D Mutant Specific) (D8H7) Rabbit mAb

RRID:AB\_2728748

Type: Antibody

---

### Proper Citation

Cell Signaling Technology Cat# 14429, RRID:AB\_2728748

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2728748](http://antibodyregistry.org/AB_2728748)

**Proper Citation:** Cell Signaling Technology Cat# 14429, RRID:AB\_2728748

**Target Antigen:** Ras (G12D Mutant Specific)

**Host Organism:** rabbit

**Clonality:** recombinant monoclonal

**Comments:** Applications: WB

**Antibody Name:** Ras (G12D Mutant Specific) (D8H7) Rabbit mAb

**Description:** This recombinant monoclonal targets Ras (G12D Mutant Specific)

**Target Organism:** human

**Clone ID:** D8H7

**Antibody ID:** AB\_2728748

**Vendor:** Cell Signaling Technology

**Catalog Number:** 14429

**Alternative Catalog Numbers:** 14429S

**Record Creation Time:** 20250819T213559+0000

**Record Last Update:** 20250819T232918+0000

---

### Ratings and Alerts

No rating or validation information has been found for Ras (G12D Mutant Specific) (D8H7) Rabbit mAb.

No alerts have been found for Ras (G12D Mutant Specific) (D8H7) Rabbit mAb.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 20 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Ialchina R, et al. (2026) Microenvironmental acidosis drives PARP- and ATM inhibitor resistance in p53 deficient pancreatic cancer. *iScience*, 29(3), 115112.

England FJ, et al. (2025) Sustained NF- $\kappa$ B activation allows mutant alveolar stem cells to co-opt a regeneration program for tumor initiation. *Cell stem cell*, 32(3), 375.

Decker M, et al. (2025) In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer. *bioRxiv : the preprint server for biology*.

Gong Y, et al. (2025) CRISPR-Cas9 screening reveals G2E3 as a novel ubiquitin-linked factor controlling autophagosome-lysosome fusion and cancer cell progression. *Cell death discovery*, 11(1), 455.

Liu C, et al. (2025) Harmine suppresses pancreatic cancer through DYRK1A-mediated hyper-activated RAS/MAPK inhibition. *Biochemical pharmacology*, 242(Pt 1), 117291.

Yang C, et al. (2025) KRAS4B oncogenic mutants promote non-small cell lung cancer progression via the interaction of deubiquitinase USP25 with RNF31. *Developmental cell*, 60(12), 1768.

Chen Y, et al. (2025) GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer. *Cell reports*, 44(6), 115774.

Budagyan K, et al. (2025) KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation. *Cell reports*, 44(4), 115444.

Khine HEE, et al. (2025) Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways. *Scientific reports*, 15(1), 11376.

Hibshman PS, et al. (2025) Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. *Science signaling*, 18(906), eadu7145.

Biswas S, et al. (2023) Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. *Immunity*, 56(11), 2570.

Peth Z, et al. (2023) Acid-base homeostasis orchestrated by NHE1 defines the pancreatic stellate cell phenotype in pancreatic cancer. *JCI insight*, 8(19).

Han J, et al. (2023) Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer. *Genes & development*, 37(17-18), 818.

Wu Z, et al. (2023) Pericyte stem cells induce Ly6G<sup>+</sup> cell accumulation and immunotherapy resistance in pancreatic cancer. *EMBO reports*, 24(4), e56524.

Shui B, et al. (2023) Oncogenic K-Ras suppresses global miRNA function. *Molecular cell*, 83(14), 2509.

Gruber E, et al. (2022) Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells. *Cell reports*, 40(7), 111182.

Schild T, et al. (2021) NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma. *Cell reports*, 35(11), 109238.

Escobar-Hoyos LF, et al. (2020) Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. *Cancer cell*, 38(2), 198.

Lentsch E, et al. (2019) CRISPR/Cas9-Mediated Knock-Out of KrasG12D Mutated Pancreatic Cancer Cell Lines. *International journal of molecular sciences*, 20(22).

Abel EV, et al. (2018) HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. *eLife*, 7.